The US Centers for Disease Control and Prevention is currently investigating five hospitalizations that occurred in people ...
The following is a summary of “Transcriptomic insights into early mechanisms underlying post-chikungunya chronic inflammatory ...
23h
GlobalData on MSNEC approves Bavarian Nordic’s chikungunya vaccine marketingThe European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine ...
Bhopal: Health authorities in Bhopal have intensified their monitoring and preventive efforts following a roughly 10% rise in ...
Five people have been hospitalized with cardiac and neurological symptoms after getting the chikungunya vaccine.
Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...
Si l’avis est validé par la Commission Européenne, IXCHIQ® pourrait devenir le premier vaccin contre le chikungunya ...
Hyderabad: Biological E. Limited has announced a strategic partnership with Bavarian Nordic A/S to expand access to Bavarian ...
First chikungunya vaccine approved in Europe for persons as young as 12 years old. On track for launch in key European ...
If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and ...
Plus de 1.000 nouveaux cas de chikungunya ont été enregistrés en un mois à La Réunion. Face à cette rapide propagation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results